Supex is striving to build up a pipeline of novel therapeutics and to create strategic partnerships with global biotech companies. Through the use of open innovation and diverse investment strategies, Supex will look to raise the value of assets that are much needed within the healthcare sector.
The current development pipeline includes a next-generation granulocyte-colony stimulating factor (G-CSF) biobetter compound for the treatment of chemotherapy-induced neutropenia. Chemotherapy-induced neutropenia is the result of the use of chemotherapy-based cancer agents, which causes a decrease in neutrophils (a type of white blood cell) and increases the risk of infection. G-CSF agents stimulate the production of neutrophils from the bone marrow in advance of when they would normally form before the patient becomes neutropenic. Supex G-CSF biobetter compounds have shown to have an enhanced pharmacokinetic and pharmacodynamic profile compared to current G-CSF agents, with sufficient efficacy at lower dosing.
Supex is in constant search of finding novel, first-in-class therapies for indications where there is a significant unmet medical need.